Correction: Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts
Samyra R. Cox, Abhay Kadam, Sachin Atre, Akshay N. Gupte, Hojoon Sohn, Nikhil Gupte, Trupti Sawant, Vishal Mhadeshwar, Ryan Thompson, Emily Kendall, Christopher Hofmann, Nishi Suryavanshi, Deanna Kerrigan, Srikanth Tripathy, Arjunlal Kakrani, Madhusudan S. Barthwal, Vidya Mave

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsTuberculosis Research and Epidemiology · Health Systems, Economic Evaluations, Quality of Life · Chronic Disease Management Strategies
Correction: Trials 23, 635 (2022)
https://doi.org/10.1186/s13063-022-06503-6
Following publication of the original article [1], we have been notified that sputum collection has been done at the TU instead of at home, as originally stated in the paper. This change was made due to logistical constraints. The Interventions and Data collection and management sections have been modified to reflect this.
In the Sample size section, second paragraph, the phrase “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 80% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 3 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” was also modified into “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 90% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 1.7 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” (changes marked in bold).
3 was also changed into 1.7 into the Statistical Methods section (“the upper bound of this estimate is less than 1.7 per 100 person-years”). 3 per 100 person-years applied to recurrent cases only. The non-inferiority margin for the primary outcome which includes both new and recurrent cases is 1.7 per 100 person-years.
The author contribution section was also modified to include the statement: “SA and TS resigned from the study and were not involved in the discussion related to the manuscript correction.”
The original article has been corrected.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Cox SR Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts Trials 20222363510.1186/s 13063-022-06503-635932062 PMC 9354295 · doi ↗ · pubmed ↗
